进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为7084.28万元。该股近5个交易日累 计上涨4.01%，主力资金合计净流入6746.8万元。 责任编辑：小浪快报 1月9日，爱尔眼科收涨0.97%，收盘价为11.42元，发生1笔大宗交易，合计成交量22.1万股，成交金额 249.95万元。 第1笔成交价格为11.31元，成交22.10万股，成交金额249.95万元，溢价率为-0.96%，买方营业部为华泰 证券股份有限公司成都锦晖西二街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证 券营业部。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ ...

爱尔眼科1月9日大宗交易平台出现一笔成交，成交量22.10万股，成交金额249.95万元，大宗交易成交价 为11.31元，相对今日收盘价折价0.96%。该笔交易的买方营业部为华泰证券股份有限公司成都锦晖西二 街证券营业部，卖方营业部为华泰证券股份有限公司成都锦晖西二街证券营业部。 进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为7084.28万元。 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 22.10 | 249.95 | 11.31 | -0.96 | 华泰证券股份有限公司成 | 华泰证券股份有限公司成 | | | | | | 都锦晖西二街证券营业部 | 都锦晖西二街证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，爱尔眼科今日收盘价为11.42元，上涨0.97%，日换手率为0.78%，成交额为 7.11亿元，全天主力资金净流入792.30万元， ...

Core Viewpoint - The successful implementation of the EVO+ICL(V5) surgery at Shanghai Aier Eye Hospital marks a significant advancement in vision correction technology, particularly for individuals with high demands for night vision quality, offering a revolutionary "day and night high-definition" experience [1][8]. Group 1: Technology and Innovation - The EVO+ICL(V5) technology features an expanded optical zone design that effectively reduces night glare and halos, making it particularly suitable for individuals with high night vision requirements [2][4]. - The new ICL technology can correct a wide range of vision issues, accommodating myopia from 50 to 1400 degrees and astigmatism up to 600 degrees, while being reversible and not requiring corneal cutting [2][4]. - The EVO+ICL(V5) lens has an optical zone that expands to 7.6mm, significantly improving night vision by better covering the dark pupil [4]. Group 2: Material and Manufacturing - The lens is made from a unique Collamer material, which offers high biocompatibility, flexibility, effective UV blockage, and excellent long-term safety, ensuring a stable and lasting high-definition visual experience [5]. - The manufacturing process utilizes Swiss precision engineering, focusing on meticulous detail and continuous innovation to provide cutting-edge visual quality [6]. Group 3: Clinical Validation and Experience - The ICL technology has been validated through over 30 years of clinical practice, with more than 3 million lenses implanted globally across 75 countries, highlighting its reliability and acceptance among both doctors and patients [7]. - The successful surgery at Shanghai Aier Eye Hospital reflects the institution's strong technical capabilities, supported by a history of completing 550,000 ICL surgeries by 2025 and extensive experience in correcting high myopia and complex refractive errors [8][9]. Group 4: Future Directions - The hospital aims to continue introducing and applying globally leading technologies to meet the diverse and refined visual needs of urban residents, emphasizing a patient-centered approach in providing safe, precise, and clear vision correction solutions [9].

Group 1 - The company, Aier Eye Hospital Group, focuses on ophthalmology and is committed to keeping up with advancements in interdisciplinary fields [1]

Group 1 - The core viewpoint of the article is that Aier Eye Hospital (300015) is collaborating with iFlytek (002230) to enhance service quality through innovative applications and complementary strengths [1] Group 2 - The partnership aims to explore various application scenarios to benefit a wide range of patients [1]

Group 1 - The core viewpoint of the article is that Aier Eye Hospital (300015) has successfully achieved mass production of its "Little Green Sprout" series products, which are reported to have effective myopia prevention capabilities [1] Group 2 - The "Little Green Sprout" series products are designed to address myopia, indicating a focus on eye health and preventive care in the ophthalmology sector [1] - The announcement was made in response to investor inquiries on the company's interactive platform, highlighting the company's engagement with its investors [1]

证券日报网讯1月7日，爱尔眼科（300015）在互动平台回答投资者提问时表示，爱尔网络覆盖中国广大 城乡县域，截至2025年6月30日，公司境内医院355家，门诊部240家，详情请查阅爱尔眼科官网。 ...

格隆汇1月7日丨爱尔眼科(300015.SZ)在投资者互动平台表示，"小青葵"系列产品已实现量产。 ...

Core Viewpoint - The launch of the EVO ICL (V5) crystal implantation surgery in Gansu marks the introduction of a cutting-edge myopia correction technology, allowing local patients to access advanced treatment without traveling abroad [2][3]. Group 1: Technology and Innovation - The EVO ICL V5 crystal features a key advancement with an optical zone diameter increased from 5.8 mm to 6.1 mm, significantly enhancing night vision quality for patients, especially those with larger pupils, and reducing glare and halos [2]. - The V5 crystal improves the correction precision for moderate to low myopia to a range of 25 degrees, promoting personalized treatment options [2]. - The crystal has high biocompatibility and UV-blocking capabilities, having undergone over 30 years of clinical validation globally, making it a reliable surgical choice due to its non-cutting, safe, and reversible nature [2]. Group 2: Clinical Implementation and Recognition - The V5 technology's regular implementation in Lanzhou signifies its official approval by national authorities, allowing patients in Gansu and the northwest region to benefit from this advanced technology locally [3]. - A plaque ceremony was held to establish the "EVO ICL V5 Crystal Gansu Clinical Application Popularization Alliance," highlighting the collaboration between STAAR company and local hospitals, along with the certification of the first surgical expert in Gansu [3][5]. Group 3: Safety and Patient Experience - The V5 crystal maintains the safety foundation of its predecessor, with innovations primarily in optical design, supported by over 40 precise preoperative examinations to ensure safety and effectiveness [5]. - Different myopia correction techniques cater to various needs, with the EVO ICL (V5) particularly suited for patients with high myopia (over 600 degrees) and those requiring enhanced night vision, such as drivers [5]. - Patient testimonials shared during the event highlighted improvements in night vision and overall quality of life, resonating with the audience [5]. Group 4: Future Directions - The Lanzhou Eye Hospital plans to continue introducing global innovative technologies, ensuring a comprehensive range of surgical options and strict quality control to provide safer, more precise, and personalized visual quality enhancement solutions for patients in the northwest region [5].

证券日报网讯 1月6日，爱尔眼科在互动平台回答投资者提问时表示，公司专注眼科医疗，高度关注边 缘交叉学科的动态进展，在创新上鼓励"脑洞大开"，在工作中必须"脚踏实地"。 （文章来源：证券日报） ...